Medtronic’s Resolute® Drug-Eluting Stent Matches Market-Leading Rival in Large Head-to-Head Study

Medtronic’s Resolute® Drug-Eluting Stent Matches Market-Leading Rival in Large Head-to-Head Study
PARIS—-The highly anticipated first results of the RESOLUTE All Comers study were presented today during the late-breaking clinical trial session of the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial, the Resolute zotarolimus-eluting stent from Medtronic, Inc. was found to be as safe and effective as the Xience® V everolimus-eluting stent from Abbott Laboratories .

Read more on Business Wire via Yahoo! Finance

More Meth Drug Addiction Info:

• Abbott Laboratories (NYSE: ABT)
• BIOSENSORS LAUNCHES BIOMATRIX FLEX DRUG–ELUTING STENT
• Abbott Laboratories (ABT) goes negative by breaking below intraday …
• Broncus Technologies, Inc. – Medical Equipment – Deals and …
• Drugs and Medical Devices Associated With Heart Problems …
• United Kingdom Diabetes Care Devices Market Outlook to 2016 Report …
• Abbott Laboratories and the “India Cure” for the Ailing …
• A Bridal Makeup Artist Gives You a Perfect and Fairy like Look …
• Trial Pole Session in Melbourne for My Blog Readers « Kim Ong
• Dividend Stocks – The Dividend Daily » Blog Archive » Medtronic Q4 …